Live Breaking News & Updates on Abbvie Genentech

Stay updated with breaking news from Abbvie genentech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Venetoclax Monotherapy Leads to Durable Responses in Relapsed, Refractory CLL

The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.
....

Venetoclax Venclexta , Pharmacyclics Johnson , Abbvie Genentech , Image Credit , Brci Pretreated , Bcri Naïve , Venetoclax Monotherapy ,

Ofatumumab, Methylprednisone, Lenalidomide Regimen Feasible as Frontline Therapy in CLL/SLL

Investigators reported the regimen had a tolerable safety profile, though they said its use may be limited due to the development of newer therapies. ....

Sebastian Kaulitzki , Abbvie Genentech , Eva Sahakian , H Lee Moffitt Cancer Center , Research Institute , Clinical Lymphoma , Moffitt Cancer Center ,

Venetoclax Resistance in Patients With MDS Explained in New Study

The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes. ....

Abbvie Genentech , Nature Communications ,

Review Outlines Management of Patients Receiving Venetoclax for CLL

Risks like tumor lysis syndrome in the setting of chronic lymphocytic leukemia (CLL) require vigilant planning and coordination, authors say. ....

Venetoclax Venclexta , Pharmacyclics Janssen , Abbvie Genentech , Image Credit ,

Belantamab Mafodotin Plus Vd More Than Doubles PFS in Relapsed/Refractory Multiple Myeloma

Belantamab mafodotin plus bortezomib and dexamethasone improved PFS vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory myeloma. ....

United States , Roche Genentech , Rachid Baz , Abbvie Genentech , International Staging System , Moffitt Cancer Center , Revised International Staging System , Belantamab Mafodotin , Multiple Myeloma , Phase 3 Dreamm 7 Trial , 2024 February Asco Plenary Series , Maria Victoria Mateos , Hospital Universitario De Salamanca ,